Source comparison
BPC-157 vs Cartalax: Full Comparison
Primary Mechanism Angiogenesis + collagen synthesis via VEGF upregulation Epigenetic chromatin binding to restore age-silenced gene transcription BPC-157 acts on acute damage; Cartalax acts on aging patterns Optimal Use Case Acute injury (tendon, ligament, mus
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Angiogenesis + collagen synthesis via VEGF upregulation
- Epigenetic chromatin binding to restore age-silenced gene transcription
- BPC-157 acts on acute damage; Cartalax acts on aging patterns
- Optimal Use Case
- Acute injury (tendon, ligament, muscle tear), post-surgical healing
- Chronic degeneration (osteoarthritis, cartilage thinning, bone density loss)
- Different biological problems. Not interchangeable
- Research Timeline to Effect
- 7–21 days in animal models
- 60–180 days in human clinical studies
- BPC-157 is fast-acting; Cartalax requires sustained administration
- Evidence Base Strength
- 300+ preclinical studies, minimal human data
- 40+ studies including human trials, limited Western replication
- BPC-157 has broader preclinical support; Cartalax has clinical use history
- Administration Route
- Subcutaneous or intramuscular injection
- Oral or intramuscular injection
- BPC-157 typically requires injection; Cartalax available in oral form
- Typical Research Dosing
- 200–500 mcg daily in animal studies (human equivalent ~10–25 mcg/kg)
- 10–20 mg daily orally or 0.5–1 mg IM in human studies
- Dosing protocols differ significantly between compounds
- The comparison table underscores the fundamental point: these peptides don't compete because they address different phases of tissue health. BPC-157 is the compound of choice when repair of existing damage is the goal. Cartalax is the compound when preventing or slowing age-related decline is the priority. Research labs frequently use both in sequence. BPC-157 during acute recovery phases, Cartalax during maintenance phases.